Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616212 | 0.96 | MEN1 (0.42) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL824134 | 0.85 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRB | |
| SCHEMBL353002 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TSHRTHRB | |
| SCHEMBL1831709 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TSHRMAPK1KMT2ATHRB | |
| SCHEMBL28007316 | 0.80 | CES2 (0.46) | ALDH1A1TSHR | |
| SCHEMBL14294549 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL351841 | 0.78 | ALDH1A1 (0.42) | ALDH1A1TSHRMEN1KMT2ATHRB | |
| SCHEMBL14269234 | 0.77 | TDP1 (0.39) | ALDH1A1TSHRMEN1KMT2ATHRB | |
| SCHEMBL16352654 | 0.77 | TSHR (0.42) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1831359 | 0.77 | THRB (0.42) | ALDH1A1TSHRMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9241216-A | — | — | None | — | — | JP | disclosed |
| US-7794751-B2 | Medicament incorporation matrix | SURMODICS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20060165751-A1 | Medicament incorporation matrix | Surmodics Coatings, LLC | 2006-07-27 | — | — | US | disclosed |
| US-7056533-B2 | Medicament incorporation matrix | SURMODICS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1309360-B1 | MEDICAMENT INCORPORATION MATRIX | SURMODICS INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1309360-A2 | MEDICAMENT INCORPORATION MATRIX | SurModics, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-0738703-B1 | Acrylic acid derivatives, method for preparing the acrylic acid derivatives, and acrylic acid polymers | NIPPON CATALYTIC CHEM IND (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-20020041899-A1 | Medicament incorporation matrix | Surmodics Coatings, LLC | 2002-04-11 | — | — | US | disclosed |
| WO-2002013871-A2 | MEDICAMENT INCORPORATION MATRIX | SURMODICS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-5834576-A | CROSSLINKING USING AN ACRYLIC ESTER CONTAINING ETHER GROUPS | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| JP-H09241216-A | PURIFICATION OF ACRYLIC ESTER DERIVATIVE | NIPPON SHOKUBAI CO LTD | 1997-09-16 | — | — | JP | disclosed |
| EP-0738703-A2 | Acrylic acid derivatives, method for preparing the acrylic acid derivatives, and acrylic acid polymers | NIPPON SHOKUBAI CO., LTD. (JP) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041899-A1 | Medicament incorporation matrix | COL14A1, MATR3, ECPAS | ALDH1A1 1028/4885TSHR 4616/4885MAPK1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.